NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Helex

Helex

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.helex.bio/

Last Round

Seed

Oct 30, 2025

Total Funding Raised

$8.5M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Helex is a biotechnology company developing genomic medicines for high-burden kidney diseases using proprietary lipid nanoparticle delivery and AI-driven drug design platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Biotech Equipment, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

genomic diagnosticsbioinformatics softwareprecision medicinedrug discoverygene editingmolecular diagnosticsguide-RNA designtherapeutic designpreclinical researchbiotech R&DLNP deliverygenomic data analysisin silico drug designAI-driven drug discoverybiotech platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Helex Comparables

Compare Helex with similar companies based on industry and business-model similarity.

Helex comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Illumina, Inc.
62%
Thermo Fisher Scientific Inc.
61%
LatchBio
59%

Helex Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedOct 30, 2025
AcceleratorJan 27, 2022
AcceleratorOct 1, 2021

Key People

Founding team and executive leadership

Anirudh Nishtala

Chief Operating Officer

Executive Team

Helex Investors

Notable investors and investment history

Helex investors
InvestorRounds
pi VenturesSeed
IndieBioAccelerator
Bluehill CapitalSeed
SOSVSeed, Accelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 26, 2026

    Grew 19% QoQ, from 27 to 32 employees.

  • Oct 30, 2025

    $4M raised in Seed round.

Helex Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Helex Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Helex's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew York City, New York
Employee Range34
Year Founded2021
Last FundingOct 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.